acalabrutinib
AstraZeneca admits cancer data for acquired drug was fabricated
October 16, 2017Research and Development, Sales and Marketing Acerta, AstraZeneca, acalabrutinib
AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers …
AstraZeneca scores second accelerated FDA review in 2 days for blood cancer drug
August 1, 2017Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, acalabrutinib, biotech, drugs, life sciences, pharma, pharmaceutical
It’s been a rollercoaster week for AstraZeneca.
AstraZeneca to buy majority share in Acerta Pharma
December 17, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, mergers
Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer …
AstraZeneca in $5bn Acerta buyout talks
December 14, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover
AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
